Amberstone Biosciences develops Tumor Microenvironment Activated Therapeutics (T-MATEs) that precisely trigger immune responses in tumors while minimizing damage to healthy tissues. This technology addresses the challenge of safely harnessing the therapeutic potential of immunotherapies that have previously been deemed too toxic for clinical use.
Funding
$15M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many promising immunotherapies exhibit potent anti-tumor activity, but their clinical application is limited by harmful effects on healthy tissues. Systemic immune activation can lead to off-target toxicity, hindering the development of effective treatments for various cancers.
Solution
Amberstone Biosciences develops Tumor Microenvironment Activated Therapeutics (T-MATEs), a next-generation immunotherapy platform designed to precisely trigger immune responses within the tumor microenvironment while minimizing damage to healthy tissues. T-MATEs utilize a unique environmentally-specific conditional activation mechanism, enabling the targeting of previously intractable targets. This approach unlocks the therapeutic potential of immunotherapies that have historically been deemed too toxic for clinical use, offering a safer and more effective way to treat cancer. The T-MATEs' binding affinity switch focuses on targets that might prove otherwise too toxic to treat with traditional methods.
Target Audience
The primary target audience includes pharmaceutical companies and research institutions focused on developing novel cancer immunotherapies with improved safety and efficacy profiles.
Features
- Tumor Microenvironment Activated Therapeutics (T-MATEs) platform
- Environmentally-specific conditional activation of therapeutics
- Binding affinity switch for targeted drug delivery
- Minimized off-target toxicity and enhanced safety profile